Author

Toshifumi Hibi 1

1 Kitasato Institute Hospital Center for Advanced IBD Research and Treatment,Tokyo,Japan

A PHASE 3 STUDY OF VEDOLIZUMAB IN JAPANESE PATIENTS WITH ULCERATIVE COLITIS: EFFECTS ON TIME TO DISEASE WORSENING AND TREATMENT FAILURE

Satoshi Motoya, Kenji Watanabe, Haruhiko Ogata, Takanori Kanai, Toshiyuki Matsui, Yasuo Suzuki, Mitsuhiro Shikamura, Kenkichi Sugiura, Kazunori Oda, Tetsuharu Hori, Takahiro Araki, Mamoru Watanabe, Toshifumi Hibi

ABSENCE OF BOWEL URGENCY IS ASSOCIATED WITH IMPROVEMENTS IN CLINICAL OUTCOMES IN PATIENTS WITH ULCERATIVE COLITIS RECEIVING MIRIKIZUMAB

Marla C. Dubinsky, Remo Panaccione, James D Lewis, Bruce E. Sands, Toshifumi Hibi, Scott D. Lee, April Naegeli, Mingyang Shan, Linden Green, Nathan Morris, Vipin Arora, Alison Potts Bleakman, Ruth Belin, Simon Travis

ADALIMUMAB ACHIEVES COMPLETE REMISSION AT 52 WEEKS IN JAPANESE PATIENTS WITH INTESTINAL BEHÇET'S DISEASE

Fumihito Hirai, Satoshi Tanida, Nagamu Inoue, Makoto Naganuma, Anne Camez, Bidan Huang, Vipin Arora, Morio Ozawa, Toshifumi Hibi, Roopal B Thakkar

EFFECT OF 52 WEEKS OF MIRIKIZUMAB ON INFLAMMATORY BOWEL DISEASE QUESTIONNAIRE SCORES IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE

Laurent Peyrin-Biroulet, Bruce E. Sands, William Sandborn, Peter D.R. Higgins, Fumihito Hirai, Vipul Jairath, Ruth Belin, Yan Dong, Elisa Gomez Valderas, Debra Miller, Vipin Arora, April Naegeli, Paul Pollack, Jay Tuttle, Toshifumi Hibi

EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Brian G. Feagan, Edward V. Loftus, Jr., Silvio Danese, Severine Vermeire, William Sandborn, Tim Ritter, Rajiv Mehta, Ursula Seidler, Frank Seibold, Ian Beales, Hyo Jong Kim, John McNally, Chohee Yun, Sally Zhao, Xiaopeng Liu, Chantal Tasset, Robin Besuyen, Mamoru Watanabe, Stefan Schreiber, Gerhard Rogler, Toshifumi Hib

EFFICACY AND SAFETY OF FILGOTINIB AS MAINTENANCE THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY

Laurent Peyrin-Biroulet, Edward V. Loftus Jr., Silvio Danese, Severine Vermeire, William Sandborn, Ronald Fogel, Sandeep Nijhawan, Radoslaw Kempinski, Rafal Filip, Ihor Hospodarskyy, John McNally, Chohee Yun, Sally Zhao, Xiaopeng Liu, Chantal Tasset, Robin Besuyen, Mamoru Watanabe, Stefan Schreiber, Gerhard Rogler, Toshi

Efficacy and Safety of Mirikizumab (LY3074828) in a Phase 2 Study of Patients with Crohn's Disease

Bruce E. Sands, William Sandborn, Laurent Peyrin-Biroulet, Peter Higgins, Fumihito Hirai, Ruth Belin, Elisa Gomez Valderas, Debra Miller, MaryAnn Morgan-Cox, April Naegeli, Paul Pollack, Jay Tuttle, Toshifumi Hibi

EFFICACY AND SAFETY OF MIRIKIZUMAB AFTER 52-WEEKS MAINTENANCE TREATMENT IN PATIENTS WITH MODERATE-TO-SEVERE CROHN'S DISEASE

Bruce E. Sands, William Sandborn, Laurent Peyrin-Biroulet, Peter Higgins, Fumihito Hirai, Vipul Jairath, Geert R. D'Haens, Maria T. Abreu, Ruth Belin, Elisa Gomez Valderas, Debra Miller, April Naegeli, Vipin Arora, Paul Pollack, Jay Tuttle, Toshifumi Hibi

EFFICACY, SAFETY, AND DEMOGRAPHICS FACTOR OF ORAL TACROLIMUS THERAPY IN 666 JAPANESE PATIENTS WITH REFRACTORY ULCERATIVE COLITIS

Haruhiko Ogata, Takayuki Yamamoto, Reiko Kunisaki, Kota Ishida, Toshifumi Hibi

Impact of Mirikizumab Treatment on Inflammatory Bowel Disease Questionnaire Scores in Patients with Moderate to Severely Active Crohn's Disease

Bruce E. Sands, William Sandborn, Laurent Peyrin-Biroulet, Peter Higgins, Fumihito Hirai, Vipul Jairath, Ruth Belin, Yan Dong, Elisa Gomez Valderas, Debra Miller, MaryAnn Morgan-Cox, April Naegeli, Paul Pollack, Jay Tuttle, Toshifumi Hibi

Item 1 - 10 / 33
1
2 3 4